FDA-approved weight-management medications containing semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist) may be prescribed when clinically appropriate. AlyneMD combines medication selection with medical evaluation, tolerability-guided dosing, nutrition and muscle-preservation planning, and follow-up.
.webp)
GLP-1 receptor agonists are FDA-approved for chronic weight management and work by regulating appetite and slowing gastric emptying — you feel satisfied on less, and cravings quiet down. In clinical trials of FDA-approved GLP-1 medications, patients achieved substantial, sustained weight loss when combined with lifestyle changes. Individual results vary.
Weight management is chronic medical care, not a short-term injection plan. The right program evaluates weight history, cardiometabolic risk, medications, nutrition, muscle mass, and the factors that can make weight regain more likely. Read the physician guide to metabolic optimization →

A physician-supervised protocol that combines medication selection, response- and tolerability-guided dosing, baseline risk assessment, nutrition support, and a plan to preserve lean mass.
.webp)




.webp)
.webp)
Results shown are individual patient outcomes. Individual results vary.

GLP-1 medications are prescription-only and are not right for everyone. The most common side effects are nausea, digestive changes, and fatigue, which typically ease as your body adjusts and as dosing is titrated properly. GLP-1 medications are not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and require caution with a history of pancreatitis. Rapid weight loss without medical supervision can cost you muscle and nutrition — which is exactly why this program is physician-monitored. Every candidate completes a medical evaluation and baseline labs before any prescription is written. Read our guide to facial volume changes after GLP-1 weight loss →